Aeolus (688578.SH): Gefitinib tablets for the treatment of first-line EGFR PACC mutations in NSCLC are included in the list of breakthrough therapy varieties.

Intelligence Finance and Economics APP News, Ailis (688578.SH) announced that the company's core product Gefitinib mesylate tablets (trade name "Evasha, abbreviated as Gefitinib) has recently been included in the list of proposed breakthrough therapeutic varieties by the Drug Evaluation Center of the National Medical Products Administration. It is intended to be indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) adult patients with epidermal growth factor receptor (EGFR) PACC mutation. The public notice period is from December 25, 2025 to January 4, 2026.